Centrally authorised medicinal products (“CAPs”) put on the market of one Member State can be marketed in any other Member State by a distributor, independently of the marketing-authorisation holder (“parallel distribution”). Parallel distribution pertains to all centrally authorised products and is checked by the European Medicines Agency.
In relation to parallel distribution, the EMA has updated its guidance: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/parallel-distribution/frequently-asked-questions-about-parallel-distribution
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
No comments:
Post a Comment
Pharmaceutical Microbiology Resources